News
AGMB
13.81
+2.83%
0.38
Agomab Details NOV-ERA Phase 2b Trial Design for Ontunisertib in Fibrostenosing Crohn’s Disease
TipRanks · 3d ago
Agomab announces NOV-ERA study design
TipRanks · 3d ago
Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease
PUBT · 3d ago
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Barchart · 3d ago
Weekly Report: what happened at AGMB last week (0615-0619)?
Weekly Report · 5d ago
Agomab initiated with a Buy at H.C. Wainwright
TipRanks · 5d ago
AGOMAB THERAPEUTICS NV <AGMB.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $35
Reuters · 5d ago
U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon
Reuters · 5d ago
Weekly Report: what happened at AGMB last week (0608-0612)?
Weekly Report · 06/15 10:46
Weekly Report: what happened at AGMB last week (0601-0605)?
Weekly Report · 06/08 10:40
AgomAb Therapeutics: High Risk, High Reward Stock
Seeking Alpha · 06/04 09:11
Weekly Report: what happened at AGMB last week (0525-0529)?
Weekly Report · 06/01 10:47
Agomab Shareholders Approve All 2025 Accounts and Board Reappointments at May 26 AGM
TipRanks · 05/27 11:28
Agomab Therapeutics holds annual general meeting, backs board reappointments
PUBT · 05/27 09:00
Agomab Announces Results of Annual General Meeting
Barchart · 05/27 04:00
Weekly Report: what happened at AGMB last week (0518-0522)?
Weekly Report · 05/25 10:51
Wall Street Analysts Are Bullish on Top NA Picks
TipRanks · 05/18 13:01
Weekly Report: what happened at AGMB last week (0511-0515)?
Weekly Report · 05/18 10:50
Agomab to Participate in Upcoming Conferences
Barchart · 05/14 06:30
Weekly Report: what happened at AGMB last week (0504-0508)?
Weekly Report · 05/11 10:47
More
Webull provides a variety of real-time AGMB stock news. You can receive the latest news about AgomAb Therapeutics NV through multiple platforms. This information may help you make smarter investment decisions.
About AGMB
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.